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Introduction 
 
LKB1 is a serine/threonine protein kinase mu-
tated in patients with Peutz-Jeghers syndrome, 
an autosomal dominant genetic condition that 
predisposes to a wide spectrum of benign and 
malignant tumors [1, 2]. LKB1 functions as a 
tumor suppressor by controlling cell division [3], 
regulating cell polarity [4], and coupling cell 
growth to energy metabolism [5]. Restoring 
LKB1 expression in a number of tumor cell lines 
suppresses their growth by inducing G1 cell-
cycle arrest [6]. LKB1 is a major upstream 
kinase of AMP-activated protein kinase (AMPK), 
a master regulator of energy homeostasis and 
cell growth [7]. In addition, it activates at least 
12 other members of AMPK-related protein 
kinase family through phosphorylation of a con-
served threonine in the “T-loop” of the kinase 
domain [8]. 
 
LKB1 signaling is regulated by posttranslational 
modification and sub-cellular translocation [9-
11]. It is phosphorylated on multiple residues, 
and some of these phosphorylations (such as 
Thr336 and Ser428) have been shown to modu-
late the catalytic activity or sub-cellular localiza-
tions of this kinase [9, 12, 13]. LKB1 forms a 
heterotrimeric complex with the pseudokinase 
STE20-related adaptor protein α (STRADα) and 
the scaffolding protein mouse protein 25 
(MO25), which facilitate the activation and local-
ization of LKB1 in the cytoplasm [14-16]. Vari-
ous mutants of LKB1 discovered in human can-
cer patients accumulate predominantly to the 
nucleus and are unable to suppress cell growth 
[11, 17], suggesting that the cytosol pool of 
LKB1 plays a key role in mediating its tumor 
suppressive activities. On the other hand, the 
precise upstream signaling events that control 
the posttranslational modification and sub-
cellular translocation of LKB1 remain poorly 
characterized. 
 
The present study demonstrated that the sur-
vival kinase Akt acts as an immediate upstream 
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regulator of LKB1 to mediate the phosphoryla-
tion at Ser334, leading to an enhanced interac-
tion with 14-3-3 proteins and augmented nu-
clear retention of this kinase. Importantly, phos-
phorylation at Ser334 abolishes the tumor sup-
pressive activity of LKB1 in both human breast 
cancer cell cultures and mammary carcinoma 
implanted in nude mice. 
 
Materials and methods 
 
Antibodies, reagents and expression vectors 
 
Antibodies for Akt, LKB1, β-tubulin and CREB 
(48H2) were purchased from Cell Signaling 
Technology (Beverly, MA, USA). Antibodies for 
mouse anti-Flag M2 and β-actin were from 
Sigma (Saint Louis, MO, USA). Antibodies for 
pan-14-3-3 and 14-3-3ζ, and the specific siRNA 
for 14-3-3ζ were from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Akt inhibitor (Akti-1/2) 
was kindly provided by Dr Peter R. Shepherd 
[18]. Activated His-Akt1 was purchased from 
Calbiochem (San Diego, CA, USA). The mammal-
ian expression vector for murine LKB1 (pcDNA3-
LKB1) was a gift from Dr David Carling [7]. The 
vectors for prokaryotic expression of 14-3-3 pro-
tein isoforms and His-tagged STRADα were ob-
tained from Addgene (Cambridge, MA, USA). 
Prokaryotic expression vector encoding GST-
tagged LKB1 (GST-LKB1) was generated by sub-
cloning the mouse LKB1 cDNA into pGEX-4T-1 
vector (GE Healthcare). Site-directed mutagene-
sis was performed to construct vectors for ex-
pressing LKB1 mutants in mammalian cells 
(pcDNA3-LKB1 S334A and pcDNA-LKB1 
S334D), using the primers listed in Supplemen-
tary Table 1. The Recombinant proteins were 
produced and purified as described [19]. 
 
In vitro phosphorylation assay 
 
In vitro phosphorylation was performed by co-
incubating ten microgram of recombinant pro-
teins with 250 nanogram of activated Akt1 in 
25 μl kinase assay buffer (50 mM HEPES pH 
7.5, 10 mM MgCl2, 1 mM EGTA, 1 mM PMSF, 
0.01% Brij-35, 1 mM DTT, 1 mM Na3VO4, 1 mM 
NaF, 1×Protease Inhibitor cocktail, 2.5 μCi of [γ-
32P] ATP and 100 μM unlabelled ATP) for one 
hour at 30°C. Reactions were stopped by addi-
tion of SDS-PAGE loading buffer and boiling for 
five minutes. Samples were then separated by 
8% SDS-PAGE and radioactive signaling de-
tected by autoradiography. 
 
Cell culture and establishment of stable cell 
lines 
 
MDA-MB-231 and HEK293 cells were obtained 
from the American Type Culture Collection and 
maintained at 37°C in DMEM (Life Technolo-
gies, Grand Island, NY, USA) supplemented with 
10% fetal bovine serum. Cells were transfected 
with mammalian expression vectors encoding 
Flag-tagged LKB1 or two types of mutants 
(S334A and S334D), followed by drug-
resistance selection with G418 (1 mg/ml) [19]. 
Positive single clones were selected and then 
pooled together for subsequent characterization 
or tumor implantation. The expression of Flag-
tagged LKB1 or its mutants was confirmed by 
Western blotting analysis as described [20].  
 
Co-immunoprecipitation and GST pull-down as-
say 
 
For co-immunoprecipitation, cells were solubi-
lized in RIPA lysis buffer and the lysates incu-
bated with anti-Flag M2 affinity agarose beads 
(Sigma) at 4°C overnight on a shaking platform. 
After washing extensively with ice-cold PBS, the 
immune complexes were eluted with 0.1 M gly-
cine HCl (pH 3.0) and neutralized for SDS-PAGE 
and Western blotting analysis. 
 
GST pull-down was performed by incubating the 
cell lysates with GST-tagged proteins bound to 
Glutathione Sepharose 4B beads for 2 hours at 
4°C on a rotating platform. The beads were re-
covered by centrifugation (500 g, 15 seconds, 
4°C), washed three times with phosphate 
buffer, resuspended in SDS-PAGE loading buffer 
and then subjected to Western blotting analysis. 
 
Subcellular fractionation 
 
Cells were resuspended in a hypotonic buffer 
[10 mM Tris-HCl (pH 7.5), 25 mM KCl, 2 mM 
magnesium acetate, 1 mM DTT, 0.5 mM phenyl-
methylsulfonyl fluoride plus protease inhibitor 
cocktails] and incubated on ice for 10 minutes. 
Cell membranes were disrupted by 20 passes 
through a 25-gauge needle, and the nuclei in-
tegrity was monitored under a microscope. After 
centrifugation for five minutes at 1,000 g, the 
supernatant was harvested as the “cytoplasmic 
fraction”. The nuclear pellet was washed with 
the hypotonic buffer and lysed with RIPA buffer. 
The lysates were centrifuged at 12,000 g for 5 
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minutes and the supernatant collected as the 
“nuclear fraction”. Protein concentrations were 
determined by BCA method (Pierce Biotechnol-
ogy Inc. Rockford, USA). Equal amount of pro-
teins from cytoplasmic and nuclear fractions 
were separated by SDS-PAGE, transferred to 
PVDF membrane, and probed with specific pri-
mary antibodies to determine the expression of 
the target proteins. 
 
Immunocytochemistry 
 
Twenty-four hours prior to transfection, HEK293 
cells were seeded on coverslips. The cells were 
transiently transfected with various vectors and 
fixed with methanol. Stably-transfected MDA-MB
-231 cells were cultured on coverslips and then 
fixed with 4% paraformaldehyde. After blocking 
with 5% FBS in 1 × TBST (0.1% Triton X-100, 
0.15 M NaCl, 0.05 M Tris-HCl, pH7.4) for one 
hour, the cells were incubated with goat anti-
LKB1 antibody at 4°C for 16 hours. After three 
washes, the slides were incubated with an Alex 
Fluor 594 chicken anti-goat secondary antibody 
(Life Technologies, Grand Island, NY, USA) at a 
dilution of 1:500 for 1 hour at room tempera-
ture in dark. The slides were then rinsed, 
mounted with ProLong® Gold antifade reagent 
with DAPI (Life Technologies) and observed un-
der a fluorescence microscope (Carl Zeiss), and 
images were captured using AxioVision plus 
software. 
 
RNA interference and transfection 
 
Cells were seeded at a density of 5 × 105 cells/
well in 6-well plates and grown overnight. Spe-
cific 14-3-3ζ siRNA and control scramble siRNA 
were transfected using jetPEITM reagent 
(Polyplus-transfection SA, New York, NY, USA) 
according to manufacturer’s instructions. 48 
hours after transfection, cells were harvested 
and subjected to cellular fractionation and 
Western blotting analysis. DeliverXTM Peptide 
Transfection kit (Panomics, Santa Clara, CA, 
USA) was used for the peptide transfection. 
 
Cell counting and 3H-thymidine incorporation 
assay 
 
Cells were seeded at a density of 1 × 103 per 
well in 96-well plates. After starving in DMEM 
with 0.5% FBS for 24 hours, cells were subse-
quently stimulated with 10% FBS. At different 
time points, cells were harvested by trypsin di-
gestion and stained with trypan blue. The num-
bers of viable cells were manually counted un-
der a microscope using a hemocytometer. For 
[3H]thymidine incorporation experiment, equal 
number of cells (2 × 104 per well) was seeded in 
a 24-well plate. After starvation in DMEM con-
taining 0.5% FBS for 24 hours, the cells were 
subsequently stimulated with DMEM containing 
10% FBS. Cells were labeled with 1 μCi/ml of 
[3H-methyl] thymidine during the last six hours 
to determine the rate of DNA synthesis [21]. 
 
Cell cycle analysis 
 
Cells fixed with 70% ethanol were resuspended 
in the staining buffer [100 mM Tris pH 7.4, 150 
mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1 mg/
ml RNase, 0.1% NP-40 and 50 μg/ml propidium 
iodide] and incubated for 30 minutes. The 
analysis was carried out with EPICS® Elite ESP 
Flow Cytometer and EXPO software (Beckman 
Coulter, Miami, FL). Data were acquired from 1 x 
104 cells per sample. Gating of G0/G1-, S-, and 
G2/M-populations was performed using modfit 
3.1 software (Verity Software House, Topsham, 
ME, USA). 
 
Inoculation of breast cancer cells into nude 
mice 
 
A total number of 5×106 stably-transfected MDA
-MB-231 cells were injected into the right tho-
racic mammary fat pad of 4-week old female 
nude mice under anesthetic condition to investi-
gate the effects of LKB1 and its two mutants on 
breast cancer development. Tumors were meas-
ured using digital vernier calipers, with tumor 
volume calculated using the formula [sagittal 
dimension (mm) × cross dimension (mm)] 2/2 
and expressed in mm3. All animals were sacri-
ficed at 8 weeks after the initial implantation. 
Tumor tissues were collected, fixed in 10% neu-
tral-buffered formalin and subjected to further 
analysis. All the experimental protocols were 
approved by the Animal Ethics Committee at the 
University of Hong Kong.  
 
Data analysis 
 
All experiments were performed with four to six 
samples per group and results derived from at 
least three independent experiments. The den-
sity of protein bands were quantitatively ana-
lyzed by ImageJ software for calculating the ex-
pression ratios. Representative Western blotting 
images were shown. Values are expressed as 
mean ± SEM. All the statistical calculations 
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were analyzed with the Statistical Package for 
the Social Sciences version 11.5 software pack-
age (SPSS). Comparison between groups was 
done using Student’s unpaired t test. In all sta-
tistical comparisons, P < 0.05 was used to indi-
cate a significant difference. 
 
Results 
 
LKB1 is phosphorylated at Ser334 by Akt 
 
Tandem mass spectrometric analysis was per-
formed for Flag-tagged LKB1 purified from a 
stably-transfected HEK293 cells using 4800 
MALDI-TOF/TOFTM instrument. This analysis re-
vealed that phosphorylation occurred at six 
amino acid residues of LKB1, including Ser31, 
Thr32, Ser69, Thr71, Ser334 and Thr336. 
Among them, phosphorylations at Ser31 and 
Thr336 have been reported previously [12]. 
Analysis of LKB1 protein sequence using the 
Scansite 2.0 program (http://scansite.mit.edu) 
indicated that there was an Akt consensus 
phosphorylation motif containing the highly con-
served Ser334 and Thr336 residues (RXRXXS/
T) (Figure 1A). Therefore, an in vitro phosphory-
lation assay was performed to test whether Akt 
indeed acted as an upstream kinase of LKB1. 
GST-tagged LKB1 protein was purified from E. 
coli. Incubation of this recombinant LKB1 with 
activated Akt1 led to a distinct 32P-radiolabelled 
band (Figure 1B, top panel). In-gel trypsin diges-
tion was subsequently performed for the corre-
sponding Coomassie Brilliant Blue-stained pro-
tein bands (Figure 1B, bottom panel). Mass 
spectrometric analysis identified a unique pep-
tide with a molecular weight of 2038.04 Da ex-
isting only in LKB1 protein samples incubated 
with Akt1. De novo sequencing using QSTAR® XL 
Hybrid quadrupole-TOF mass spectrometer con-
firmed that this peptide was derived from amino 
acid 332-347 of LKB1, containing only one 
phosphor ylated residue at Ser334 
(Supplementary Figure 1). The direct interaction 
between LKB1 and Akt was further verified by 
GST-pull down assay (Figure 1C, top panel). Co-
immunoprecipitation analysis also demon-
strated that endogenous Akt interacted with 
LKB1 in HEK293 cells (Figure 1C, bottom 
panel).  
 
14-3-3 proteins interact with LKB1 via Akt-
mediated phosphorylation of Ser334 
 
Using the Scansite program, a conserved 14-3-3 
binding site (RXXSX) was found to locate within 
the same Akt consensus motif of LKB1, contain-
ing the Ser334 residue (Figure 2A). 14-3-3 pro-
teins are a family of conserved regulatory mole-
cules that bind to a multitude of intracellular 
signaling proteins and regulate the functions of 
their interacting partners [22, 23]. In vitro pull-
down analysis demonstrated that among the 
seven GST-tagged 14-3-3 proteins, robust inter-
actions could be detected between LKB1 and 
14-3-3 ζ, γ and η (Figure 2B). The interaction of 
LKB1 with endogenous 14-3-3 proteins in 
Figure 1. LKB1 is a downstream target of Akt. (A). 
Two conserved Akt consensus motifs containing 
Ser334 and Thr336 residues were found within the 
amino acid sequences of LKB1 from different spe-
cies. (B). Top panel: In vitro phosphorylation assay 
was performed by incubating recombinant active 
Akt1 with GST-LKB1 or GST. 32P-labeled phosphory-
lated LKB1 was detected by autoradiography. Bottom 
panel: The total proteins were visualized by 
Coomassie Brilliant Blue (CBB) staining. (C). Top 
panel: GST-LKB1 or GST proteins bound to Glu-
tathione Sepharose 4B beads were used for incubat-
ing with equal amount of His-tagged Akt1, and the 
associated Akt was detected by Western blot using 
its specific antibody. Bottom panel: Co-
immunoprecipitation was performed by adding anti-
Flag M2 agarose beads into the lysates of HEK293 
cells transfected with pcDNA or pcDNA3-LKB1 vec-
tors. Immune complexes were resolved by SDS-PAGE 
and the endogenous Akt associated with LKB1 de-
tected by anti-Akt antibody. 
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HEK293 cells was further confirmed by co-
immunoprecipitation using the pan 14-3-3 anti-
body (Figure 2C). 
 
To investigate whether Akt-induced phosphoryla-
tion was involved in the binding of LKB1 to 14-3-
3 proteins, HEK293 cells were pre-treated with 
Akt inhibitor (Akti-1/2) and then subjected to 
both GST-pull down and co-immunoprecipitation 
analysis. The results demonstrated that the in-
teractions between LKB1 and 14-3-3 proteins 
were significantly suppressed by treatment with 
the Akt inhibitor (Akti-1/2) (Figure 3A and 3B). 
Furthermore, mutation of Ser334 to non-
phosphorylatable alanine residue (S334A) abol-
ished the interactions between LKB1 and 14-3-
3 proteins. By contrast, S334D, a LKB1 mutant 
mimicking Akt-mediated phosphorylation, exhib-
ited much stronger interactions with 14-3-3 pro-
teins when compared to wild type LKB1 (Figure 
3C and 3D). 
 
Phosphorylation at Ser334 promotes the nu-
clear accumulation of LKB1 
 
Sub-cellular fractionation and immuno-
fluorescence staining analysis demonstrated 
that wild type LKB1 was present in both nucleus 
and cytoplasm, whereas treatment with Akt in-
hibitor Akti-1/2 promoted the translocation of 
LKB1 from nuclei to cytosol (Figure 4A and 4B). 
S334A mutation enhanced the cytosolic local-
ization of LKB1 (Figure 4C and 4D). By contrast, 
the S334D mutant was located predominantly 
in the nucleus and barely detectable in the cyto-
plasm. 
 
In HEK293 cells, 14-3-3ζ was the most abun-
dant isoform of 14-3-3 proteins (data not 
shown). Transfection with specific siRNA re-
duced the amount of 14-3-3ζ by ~50% (Figure 
5A). The reduction of 14-3-3ζ significantly pro-
moted the translocation of LKB1 from nucleus 
to cytoplasm (Figure 5B). Moreover, treatment 
with difopein, the dimeric 14-3-3 peptide inhibi-
tor [24], profoundly reduced the amount of 14-3
-3 proteins associated with LKB1 (Figure 5C). 
Notably, the decreased interaction between 
LKB1 and 14-3-3 proteins was accompanied by 
an enhanced translocation of LKB1 from nu-
cleus to cytoplasm (Figure 5D). Downregulation 
or inhibition of 14-3-3 proteins elicited similar 
effects on promoting the nuclear-cytoplasmic 
shuttling of S334D mutant (Supplementary Fig-
ure 2). 
 
The association of STRADα, a cofactor of LKB1 
that facilitates its cytoplasmic localization [16], 
was significantly enhanced by S334A, but at-
tenuated by S334D mutagenesis (Figure 6A). 
Inhibition of Akt further elevated the amount of 
STRADα associated with LKB1 (Figure 6B). 
Figure 2. LKB1 interacts with 14-3-3 proteins. (A). A 
conserved 14-3-3 binding site was found in LKB1 
sequences containing the Ser334 residue. (B). Equal 
amounts of the seven GST-tagged 14-3-3 isoforms 
were cross-linked to the Glutathione Sepharose 4B 
beads and incubated with cell lysates from HEK293 
cells overexpressing Flag-tagged wild type LKB1. The 
proteins bound to 14-3-3 isoforms were detected by 
Western blotting analysis using an anti-Flag antibody. 
(C). The lysates of HEK293 cells transfected with 
pcDNA or pcDNA3-LKB1 vectors were incubated with 
anti-Flag M2 agarose beads. Total cell lysates or im-
munoprecipitated complexes (IP) were resolved by 
SDS-PAGE and analyzed by Western blotting using 
anti-Flag or anti-pan-14-3-3 antibody. 
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Taken together, these results demonstrate that 
Akt-mediated phosphorylation and the interac-
tion with 14-3-3 proteins act synergistically to 
facilitate the nuclear retention of LKB1. 
 
Phosphorylation of LKB1 at Ser334 modulates 
its tumor suppressor activity 
Figure 3. The interaction between 14-3-3 and LKB1 is 
dependent on the phosphorylation of LKB1 at 
Ser334. (A). GST-14-3-3ζ bound to Glutathione 
Sepharose 4B beads was incubated with the cell 
lysates of HEK293 cells treated with DMSO (vehicle 
control) or 10 μM Akti-1/2. The endogenous LKB1 
associated with GST-14-3-3ζ was detected by West-
ern blotting using an anti-LKB1 antibody. (B). 
HEK293 cells overexpressing Flag-tagged wild type 
LKB1 were treated with or without 10 μM Akti-1/2, 
followed by co-immunoprecipitation using anti-Flag 
M2 agarose beads. 14-3-3 proteins associated with 
Flag-tagged LKB1 were detected by Western blotting 
using an anti-pan-14-3-3 antibody. (C). HEK293 cells 
overexpressing wild type LKB1 (WT), S334A, or 
S334D were incubated with GST-14-3-3ζ-bound Glu-
tathione Sepharose 4B beads, and the immunopre-
cipitated proteins were detected by Western blotting 
using an anti-Flag antibody. (D). HEK293 cells overex-
pressing wild type LKB1 (WT), S334A or S334D were 
subjected to co-immunoprecipitation using anti-Flag 
M2 agarose beads, and endogenous 14-3-3 proteins 
associated with Flag-LKB1 were detected by Western 
blotting using an anti-pan-14-3-3 antibody. The rela-
tive ratios of the protein bands in Western blotting 
results were calculated and presented as the means 
± SEM from at least three independent experiments. 
* P <0.05 vs corresponding controls. 
Figure 4. Phosphorylation at Ser334 modulates the 
sub-cellular localization of LKB1 in HEK293 cells. 
(A). Cells stably overexpressing Flag-tagged wild type 
LKB1 were treated with vehicle control (DMSO) or 10 
μM Akti-1/2 for 24 hours. The distribution of LKB1 in 
nuclear (Nuc) and cytosolic (Cyt) fractions was ana-
lyzed by Western blotting using an anti-Flag antibody. 
CREB and β-tubulin were used as the nuclear and 
cytosolic marker, respectively. (B). Immunofluores-
cence staining was performed for LKB1 (red) in cells 
treated with vehicle control or Akti-1/2 as in panel A. 
The images were merged with those of DAPI-stained 
nuclei (blue). Magnification, 400×. (C). Sub-cellular 
distribution of wild type LKB1 and its two mutants 
(S334A and S334D) in HEK293 cells was deter-
mined by cell fractionation and Western blotting 
analysis as in panel A. (D). Immunofluorescence 
staining for LKB1 and its two mutants expressed in 
HEK293 cells was performed and results presented 
as in panel B. The relative ratios of the protein bands 
in Western blotting results were calculated and pre-
sented as the means ± SEM from at least three inde-
pendent experiments. * P <0.05 vs corresponding 
controls. 
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The anti-proliferative effects of wild type LKB1, 
S334A and S334D mutants were evaluated in 
MDA-MB-231 human breast cancer cells. To 
this end, stable-expression clones of MDA-MB-
231 cells were established by transfection with 
plasmids encoding wild type LKB1 or each of 
the two mutants (S334A and S334D). The pro-
tein expression levels of the three versions of 
Flag-tagged LKB1 were comparable as demon-
strated by Western blotting analysis 
(Supplementary Figure 3A). Their intracellular 
distributions were similar to those observed in 
HEK293 cells, with S334A mutant mainly local-
ized in the cytoplasm and S334D mutant accu-
mulated predominantly within the nucleus 
(Supplementary Figure 3B). Cell number count-
ing results showed that wild type LKB1 and 
S334A dramatically reduced the cell prolifera-
tion rate of MDA-MB-231 cells, whereas S334D 
lost the anti-growth activity (Figure 7A). Consis-
tently, 3H-thymidine incorporation experiment 
revealed that S334D virtually had no effects on 
DNA synthesis (Figure 7B). Note that the sup-
Figure 5. 14-3-3 proteins are required for Akt-
mediated nuclear accumulation of LKB1. (A). 
HEK293 cells were transfected with scramble control 
or 14-3-3ζ-specific siRNA (si14-3-3ζ). After 48 hours, 
the level of 14-3-3ζ was detected by Western blotting 
using an anti-14-3-3ζ antibody. (B). The effects of 14-
3-3ζ knocking down on sub-cellular distribution of 
LKB1 were evaluated in the nuclear (Nuc) and cytoso-
lic (Cyt) fractions of HEK293 cells stably overexpress-
ing Flag-tagged wild type LKB1. Western blotting was 
performed using an anti-Flag antibody. (C). HEK293 
cells stably overexpressing Flag-tagged wild type 
LKB1 were transfected with or without difopein, and 
subjected to co-immunoprecipitation using anti-Flag 
M2 agarose beads. 14-3-3 proteins associated with 
LKB1 were detected by Western blotting using an anti
-pan-14-3-3 antibody. (D). The nuclear and cytosolic 
fractions of Flag-tagged wild type LKB1 in cells 
treated with or without difopein were detected using 
an anti-Flag antibody. The relative ratios of the pro-
tein bands in Western blotting results were calcu-
lated and presented as the means ± SEM from at 
least three independent experiments. * P <0.05 vs 
corresponding controls. 
Figure 6. Phosphorylation of LKB1 at Ser334 re-
duces the complex formation with STRADα. (A). 
HEK293 cells stably overexpressing wild type LKB1 
(WT), S334A or S334D were transfected with 
plasmid encoding His-tagged STRADα or an empty 
control vector (pcDNA). After 48 hours, cells were 
harvested and subjected to co-immunoprecipitation 
using anti-Flag M2 agarose beads. STRADα bound to 
LKB1 was detected by Western blotting using the 
specific antibody. (B). HEK293 cells stably 
overexpressing Flag-tagged wild type LKB1 were 
transfected with plasmid encoding His-tagged 
STRADα. After starvation in DMEM containing 0.5 % 
FBS for 24 hours, cells were treated with or without 
10 μM Akti-1/2 for another 24 hours. The associa-
tion of STRADα with LKB1 was determined by co-
immunoprecipitation followed by Western blotting 
analysis as in panel A. The relative ratios of the pro-
tein bands in Western blotting results were calcu-
lated and presented as the means ± SEM from at 
least three independent experiments. * P <0.05 vs 
corresponding controls. 
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pressive effects of LKB1 on DNA synthesis were 
significantly augmented by S334A mutation. 
Flow cytometric analysis showed that ~62% of 
cells overexpressing wild type LKB1 and ~73% 
of cells overexpressing S334A were arrested in 
G1 phase after serum stimulation (Figure 7C). 
By contrast, much less percentage of cells was 
distributed in G1 phase for the control group 
and those overexpressing S334D (~48% and 
~45%, respectively). 
 
The stably-transfected MDA-MB-231 cells were 
subsequently implanted into the mammary fat 
pads of female nude mice (106 cells per animal) 
and the tumor development monitored regularly 
after initial implantation. Tumors originated from 
control cells and those overexpressing S334D 
were palpable as early as 6 days after initial 
inoculation, whereas the onset time of tumors 
derived from cells overexpressing wild type 
LKB1 and S334A was delayed to around 14 and 
18 days, respectively (Figure 8A). Tumor growth 
was significantly suppressed by overexpression 
of wild type LKB1 (Figure 8B). The growth of 
MDA-MB-231 tumors was almost abolished by 
S334A mutation. The tumor weights of cells 
overexpressing wild type LKB1 and S334A were 
significantly reduced by ~69 % and ~88 %, re-
spectively, compared to the control group 
(Figure 8C). On the contrary, the tumors derived 
from cells overexpressing LKB1 S334D showed 
similar tumor growth rate and slightly higher 
tumor weight compared with those of the con-
trol group (Figure 8B and 8C). 
 
Immunohistochemical staining of proliferating 
cell nuclear antigen (PCNA) was performed in 
tumor sections derived from the above mice. 
The analysis revealed that over 70% and 80% of 
cells showed positive staining in control and 
S334D groups, respectively (Figure 8D). On the 
other hand, there were only ~20 % of PCNA 
positive cells in wild type LKB1 group and less 
than 5 % in S334A group. These results demon-
strated that phosphorylation occurred at 
Ser334 essentially blocked the tumor suppres-
sive activity of LKB1 in mice models. 
 
Discussion 
 
Akt kinases are the key regulators of diverse 
cellular processes, including cell survival and 
growth, protein synthesis, angiogenesis and 
glucose metabolism [25, 26]. Akt signaling is 
frequently altered in cancer [27, 28]. Hyperacti-
vation of Akt has been documented in a wide 
Figure 7. Phosphorylation at Ser334 inhibits the anti-
proliferative activity of LKB1 in human MDA-MB-231 
breast cancer cells. Cells stably overexpressing wild 
type LKB1 (WT), S334A or S334D were established 
as described in Figure 4. (A). The proliferation rates of 
the stably-transfected MDA-MB-231 cells were ana-
lyzed by manually counting the cell numbers at differ-
ent time points. (B). DNA synthesis rates were 
determined by 3H-thymidine incorporation assay and 
expressed as fold changes over pcDNA-transfected 
control cells. (C). The stably-transfected MDA-MB-231 
cells were starved with DMEM containing 0.5% FBS 
for 48 hours and stimulated with DMEM containing 
10% FBS for another 24 hours. The cell cycle 
distribution was analyzed by flow cytometry. The re-
sults are presented as the means ± SEM. * P < 0.05 
and ** P < 0.01 vs pcDNA groups; # P < 0.05 vs WT 
groups (unpaired t test, n = 6).  
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range of sporadic human cancers as well as in 
dominantly inherited cancer syndromes [29-33]. 
The present study demonstrates that the tumor 
suppressor LKB1 is a downstream target of Akt. 
The suppressive effects of LKB1 on cell prolif-
eration and tumorigenesis are abolished by Akt-
mediated phosphorylation at Ser334. 
LKB1 is generally considered to be constitu-
tively active [9]. Nuclear-cytoplasmic shuttling of 
LKB1 represents an important mechanism con-
tributing to its signaling specificity and target 
accessibility in mammalian cells [16]. For exam-
ple, activation of AMPK, a key downstream tar-
get of LKB1, occurs mainly in the cytoplasm [5]. 
STRADα enhances LKB1 activity primarily by 
promoting its translocation from nuclei to cyto-
plasm [16]. The cytoplasmic portion of LKB1 is 
responsible for its cell cycle arrest and tumor 
suppressive activities [14]. Previous studies 
have demonstrated that phosphorylation of 
LKB1 at Ser307 and Ser428 may increases its 
cytoplasmic localization [13, 34]. However, the 
upstream signaling pathways that control the 
nuclear-cytoplasmic shuttling of LKB1 remain 
unclear. Evidence in the present study demon-
strated that Akt regulates the sub-cellular local-
ization of LKB1 by promoting a phosphorylation-
dependent interaction with 14-3-3 proteins. 
LKB1 mutant S334A, which cannot be phos-
phorylated by Akt, localizes predominantly to 
cytoplasm and exhibits much more potent inhi-
bition on human breast cancer cell proliferation 
and tumorigenesis. By contrast, the LKB1 mu-
tant S334D, which mimics Akt-mediated phos-
phorylation, is accumulated mainly in the nu-
cleus and displays impaired anti-tumor activity. 
 
The 14-3-3 proteins play important roles in 
regulating cell fate and tumor development by 
integrating diversed signaling pathways [23]. 
They interact with a plethora of intracellular sig-
naling molecules in a serine/theronine phos-
phorylation-dependent manner [22]. One of the 
important regulatory functions of 14-3-3 pro-
teins is to control the sub-cellular distributions 
of their binding partners [35]. For example, 14-3
-3 proteins increase the nuclear localization of 
telomerase and p53 [36, 37]. Results of the 
present study suggest that phosphorylation-
dependent interactions with 14-3-3 proteins 
promote the nuclear sequestration of LKB1 and 
prevent the association of this kinase with 
STRADα. Note that LKB1 mutants with defective 
binding to STRADα also loss their cell-cycle ar-
rest activity [14]. Likewise, the S334D mutant 
that exhibits augmented interaction with 14-3-3 
proteins but impaired association with STRADα 
is mainly localized within nucleus and unable to 
elicit the tumor suppressor activity. 
 
The present study uncovers a molecular path-
way whereby the sub-cellular localization of 
LKB1 is regulated by the survival kinase Akt, 
Figure 8. Phosphorylation of LKB1 at Ser334 attenu-
ates its tumor-suppressive activity in nude mice 
transplanted with human MDA-MB-231 breast cancer 
cells. Same numbers (5 × 105) of stably transfected 
MDA-MB-231 cells were implanted into the mammary 
fat pads of female nude mice. (A). Tumor onset day 
was recorded as the first day of the palpable tumor 
formation. (B). Tumor growth was monitored weekly 
by measuring the tumor sizes and calculated as tu-
mor volume as described in Methods. (C). At eight 
weeks after implantation, mice were sacrificed for 
tissue collection. Representative tumor development 
images were shown in left panel and the wet weights 
of tumors measured and recorded in the right panel. 
(D). Representative microscopic images of PCNA-
stained tumor sections from the four groups of mice. 
Positive-stained cells were manually counted and 
calculated as percentage against total cells. Scale 
bar = 200 μm. The results are exhibited as the 
means ± SEM. * P < 0.05 and ** P < 0.01 vs pcDNA 
groups; # P < 0.05 vs WT groups (unpaired t test, n = 
6). 
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through both phosphorylation modification and 
protein-protein interactions (Figure 9). Spatial 
regulation represents a key mechanism 
whereby activated Akt exerts its functions to 
promote cell survival and tumorigenesis [38]. 
Notably, Akt-induced sub-cellular redistribution 
of its substrates is often mediated by 14-3-3 
proteins [39]. For instance, Akt inactivates 
FKHRL1 and p27Kip1 by inducing a phosphory-
lation-dependent association with 14-3-3 pro-
teins [40, 41]. Unlike these two examples show-
ing increased cytoplasmic localization, Akt-
induced association of LKB1 with 14-3-3 pro-
teins leads to augmented nuclear retention of 
LKB1, indicating a complex role of Akt in regu-
lating the nuclear-cytoplasmic transport of its 
downstream targets. In fact, aberrant Akt signal-
ing is an important contributor to the develop-
ment of LKB1-deficient tumors [25]. On the 
other hand, ectopic expression of LKB1 nega-
tively regulates the Akt signaling pathway [42]. 
These findings collectively suggest the existence 
of a negative feedback regulation between 
LKB1 and Akt, two kinases with opposite effects 
on cell survival, proliferation and tumorigenesis. 
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Supporting Information 
 
Material and Methods: 
Mass spectrometry analysis. Protein bands were excised from coomassie brilliant blue-stained 
gels. After reduction with DTT and alkylation with iodoacetamide, the gel pieces were digested with 
trypsin and the peptide fragments desalted with C18 Ziptip (Millipore, Billerica, MA, USA). The 
tryptic mixture was mixed at 1:1 ratio with CHCA matrix and spotted onto a MALDI target. Mass 
spectra (MS) were acquired using a 4800 MALDI-TOF/TOF instrument (Applied Biosystems, Foster 
City, CA). External calibration was performed using Calmix 1 and 2 (Applied Biosystems) at a mass 
tolerance of 100 ppm. For MS analysis, laser intensity of 2500 was used and 8 sub-spectra with 
50 shots each were acquired for every sample spot. Peak lists were created from the raw data by 
4000 series Explorer™ software (v3.5, Applied Biosystems) using the following peak filter settings: 
mass range 900–4000 Da (MS), and minimal S/N 5. Keratin and trypsin autodigestion peaks 
were excluded. For MS/MS analysis, laser intensity of 3100 was used. The precursor tolerance 
was 0.2 Da and the MS/MS precursor resolution was set at 350. Twenty-five sub-spectra with 
2500 shots were acquired for each sample spot with a metastable suppressor on. The MS/MS 
data were analyzed using GPS explorer software (v3.6, Applied Biosystems) and the MS/MS 
peptide identifications were achieved by database comparisons using an in-house MASCOT v2.1 
(Matrix Science) searching engine. Trypsin was selected as enzyme taking into consideration of 
one missed cleavage site and variable protein modifications were allowed. For protein and peptide 
identification, the significant probability scores with a p value of less than 0.05 were accepted. All 
identified peptides were confirmed by manual de novo sequencing using the QSTAR XL hybrid 
quadrupole-TOF mass spectrometer (Applied Biosystems). The peptides were electrosprayed into 
the mass spectrometer with a distally applied spray voltage of 1.8 kV. MS/MS analysis was 
performed with one full-range mass scan (m/z 400–3000) followed by information-dependent 
data acquisition scan for the selected ion. MS/MS control, data acquisition, and spectral 
processing were carried out using Analyst and BioAnalyst™ software (Applied Biosystems). Three 
independent experiments were conducted using different batches of protein samples. 
 
 
Supplementary Table 1. Sequences of primers used for site-directed mutagenesis  
Mutants Sequences  
S334A Forward: 5’AAGGACCGCTGGCGCGCTATGACTGTAGTGCCCTAC 3’ 
Reverse: 5’ GTAGGGCACTACAGTCATAGCGCGCCAGCGGTCCTT 3’ 
S334D Forward: 5’ AAGGACCGCTGGCGCGATATGACTGTAGTGCCCTAC 3’ 
Reverse: 5’ GTAGGGCACTACAGTCATATCGCGCCAGCGGTCCTT 3’ 
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Supplementary Figure 1. Mass spectrometry and de novo sequencing analysis of tryptic peptides 
of LKB1 protein collected from the in vitro phosphorylation assay. Peptide mass finger printing was 
performed using a MALDI-TOF/TOF mass spectrometer and the differentially expressed peptides 
analyzed by tandem mass spectrometry using a QSTAR XL hybrid quadrupole-TOF mass 
spectrometer as described in Methods. The de novo sequencing results revealed a 
mono-phosphorylated peptide (MW: 2038.04 Da) containing the phosphorylated Ser334 residue.  
Supplementary Figure 2 
 
Supplementary Figure 2. 14-3-3 proteins are required for Akt-mediated nuclear accumulation of 
S334D mutant. (A). The effects of 14-3-3ζ knocking down on sub-cellular distribution of S334D 
were evaluated in the nuclear (Nuc) and cytosolic (Cyt) fractions of HEK293 cells stably 
overexpressing Flag-tagged LKB1 S334D mutant. Western blotting was performed using an 
anti-Flag antibody. (B). HEK293 cells stably overexpressing Flag-tagged LKB1 S334D mutant were 
transfected with or without difopein. The S334D contents in nuclear and cytosolic fractions were 
detected using an anti-Flag antibody. The relative ratios of the protein bands in Western blotting 
results were calculated and presented as the means ± SEM from at least three independent 
experiments. *, P < 0.05 vs corresponding controls. 
Supplementary Figure 3 
 
Supplementary Figure 3. Phosphorylation of LKB1 at Ser334 modulates its sub-cellular 
localization in MDA-MB-231 breast cancer cells. Stably-transfected MDA-MB-231 cells were 
established as described in Methods. (A). Western blotting was performed for measuring the 
protein expression levels of Flag-tagged wild type LKB1 and the two mutants (S334A and S334D) 
in the stably-transfected cells. (B). Intracellular localizations of the three types of LKB1 variants 
were analyzed by immunofluorescence staining using the anti-Flag antibody (red). The images 
were merged with those stained with DAPI (blue). Magnification, 400 ×.  
 
